CL2023003102A1 - Vectores aavrh74 para la terapia génica de las distrofias musculares. - Google Patents
Vectores aavrh74 para la terapia génica de las distrofias musculares.Info
- Publication number
- CL2023003102A1 CL2023003102A1 CL2023003102A CL2023003102A CL2023003102A1 CL 2023003102 A1 CL2023003102 A1 CL 2023003102A1 CL 2023003102 A CL2023003102 A CL 2023003102A CL 2023003102 A CL2023003102 A CL 2023003102A CL 2023003102 A1 CL2023003102 A1 CL 2023003102A1
- Authority
- CL
- Chile
- Prior art keywords
- gene therapy
- muscular dystrophies
- aavrh74
- vectors
- aavrh74 vectors
- Prior art date
Links
- 238000001415 gene therapy Methods 0.000 title 1
- 201000006938 muscular dystrophy Diseases 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/015—Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
- C12N15/8645—Adeno-associated virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163179097P | 2021-04-23 | 2021-04-23 | |
| US202263327410P | 2022-04-05 | 2022-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023003102A1 true CL2023003102A1 (es) | 2024-07-12 |
Family
ID=81648417
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023003102A CL2023003102A1 (es) | 2021-04-23 | 2023-10-18 | Vectores aavrh74 para la terapia génica de las distrofias musculares. |
| CL2024002556A CL2024002556A1 (es) | 2021-04-23 | 2024-08-27 | Proteína de la cápsida de aavrh74; partícula de aavrh74; composición; y su uso. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024002556A CL2024002556A1 (es) | 2021-04-23 | 2024-08-27 | Proteína de la cápsida de aavrh74; partícula de aavrh74; composición; y su uso. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20240181083A1 (https=) |
| EP (1) | EP4326857A2 (https=) |
| JP (1) | JP2024514962A (https=) |
| KR (1) | KR20240000542A (https=) |
| AU (1) | AU2022262407A1 (https=) |
| BR (1) | BR112023021495A2 (https=) |
| CA (1) | CA3217649A1 (https=) |
| CL (2) | CL2023003102A1 (https=) |
| CO (1) | CO2023015911A2 (https=) |
| IL (1) | IL307881A (https=) |
| MX (1) | MX2023012509A (https=) |
| TW (1) | TW202304954A (https=) |
| WO (1) | WO2022226289A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2714007T3 (es) | 2007-04-09 | 2019-05-24 | Univ Florida | Composiciones de vectores rAAV que tienen proteínas de la cápside modificadas en tirosina y métodos para su uso |
| US10294281B2 (en) | 2012-05-15 | 2019-05-21 | University Of Florida Research Foundation, Incorporated | High-transduction-efficiency rAAV vectors, compositions, and methods of use |
| US12358954B2 (en) | 2012-05-15 | 2025-07-15 | University Of Florida Research Foundation, Incorporated | Capsid-modified rAAV vector compositions and methods therefor |
| KR20240095539A (ko) | 2021-10-08 | 2024-06-25 | 디노 테라퓨틱스, 인코포레이티드 | 캡시드 변이체 및 이의 사용 방법 |
| WO2024184781A1 (en) * | 2023-03-03 | 2024-09-12 | Universitat Heidelberg | Engineered aav capsids |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ701693A (en) * | 2012-04-18 | 2017-02-24 | The Children’S Hospital Of Philadelphia | Composition and methods for highly efficient gene transfer using aav capsid variants |
| US10900053B2 (en) | 2014-11-21 | 2021-01-26 | University Of Florida Research Foundation, Incorporated | Genome-modified recombinant adeno-associated virus vectors |
| WO2021030764A1 (en) * | 2019-08-14 | 2021-02-18 | University Of Florida Research Foundation, Incorporated | Aav capsid variants for gene therapy |
-
2022
- 2022-04-22 JP JP2023565307A patent/JP2024514962A/ja active Pending
- 2022-04-22 BR BR112023021495A patent/BR112023021495A2/pt unknown
- 2022-04-22 TW TW111115475A patent/TW202304954A/zh unknown
- 2022-04-22 IL IL307881A patent/IL307881A/en unknown
- 2022-04-22 MX MX2023012509A patent/MX2023012509A/es unknown
- 2022-04-22 AU AU2022262407A patent/AU2022262407A1/en active Pending
- 2022-04-22 CA CA3217649A patent/CA3217649A1/en active Pending
- 2022-04-22 WO PCT/US2022/025916 patent/WO2022226289A2/en not_active Ceased
- 2022-04-22 US US18/287,711 patent/US20240181083A1/en active Pending
- 2022-04-22 US US17/727,007 patent/US20220347317A1/en not_active Abandoned
- 2022-04-22 KR KR1020237039756A patent/KR20240000542A/ko active Pending
- 2022-04-22 EP EP22723290.7A patent/EP4326857A2/en active Pending
-
2023
- 2023-10-18 CL CL2023003102A patent/CL2023003102A1/es unknown
- 2023-11-22 CO CONC2023/0015911A patent/CO2023015911A2/es unknown
-
2024
- 2024-08-27 CL CL2024002556A patent/CL2024002556A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023021495A2 (pt) | 2023-12-19 |
| IL307881A (en) | 2023-12-01 |
| US20220347317A1 (en) | 2022-11-03 |
| AU2022262407A1 (en) | 2023-10-26 |
| MX2023012509A (es) | 2024-01-03 |
| WO2022226289A3 (en) | 2023-03-02 |
| CO2023015911A2 (es) | 2023-11-30 |
| EP4326857A2 (en) | 2024-02-28 |
| US20240181083A1 (en) | 2024-06-06 |
| AU2022262407A9 (en) | 2023-11-09 |
| CL2024002556A1 (es) | 2025-01-10 |
| JP2024514962A (ja) | 2024-04-03 |
| TW202304954A (zh) | 2023-02-01 |
| WO2022226289A2 (en) | 2022-10-27 |
| CA3217649A1 (en) | 2022-10-27 |
| KR20240000542A (ko) | 2024-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023003102A1 (es) | Vectores aavrh74 para la terapia génica de las distrofias musculares. | |
| IL279918A (en) | Gene therapy vectors for treatment of danon disease | |
| IL285238A (en) | Gene therapy vectors for treatment of danon disease | |
| JP1747355S (ja) | 筋肉マッサージ器 | |
| EP3746100A4 (en) | GENE THERAPY FOR BELT MUSCULAR DYSTROPHY TYPE 2C | |
| PT3990005T (pt) | Cistationina beta-sintetase peguilada para terapia enzimática para tratamento de homocistinúria | |
| PT3827004T (pt) | Derivados da 4-(1,3,4-oxadiazol-2-il)piridin-2(1h)-ona como inibidores da histona desacetilase 6 (hdac6) para o tratamento de infeções e.g. | |
| MX392523B (es) | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar | |
| MA43020A (fr) | Nouveaux dérivés d'imidazo[4,5-b]pyridine utilisés comme inhibiteurs de dyrk1/clk1 doubles | |
| LT3864053T (lt) | Rms gydymas, pakeičiant terapiją | |
| JP1778652S (ja) | マッサージ器 | |
| EP4356127A4 (en) | THERAPEUTIC OLIGONUCLEOTIDE METHODS | |
| EP4282481C0 (fr) | Sequences siarn ciblant l'expression des genes jak1 humains pour une utilisation therapeutique | |
| IL311499A (en) | Frataxin gene therapy | |
| EP4294402A4 (en) | THERAPEUTIC PROCEDURES | |
| ES1218143Y (es) | Fresa para el tratamiento de la perimplantitis | |
| JP1747377S (ja) | 筋肉マッサージ器 | |
| JP1743141S (ja) | 筋肉マッサージ器 | |
| JP1709518S (ja) | 筋肉マッサージ器 | |
| PL4216944T3 (pl) | Nowa koncepcja terapii do leczenia infekcji korona, w szczególności infekcji COVID-19 | |
| HK40104868A (en) | Aavrh74 vectors for gene therapy of muscular dystrophies | |
| EP4243873C0 (en) | NUCLEASE-ACTIVATED THERAPEUTIC OLIGONUCLEOTIDES | |
| ES3064459A1 (es) | Nanomaterial selectivo para el tratamiento de enfermedades parasitarias | |
| EP4509324A4 (en) | TREATMENT SOLUTION | |
| ES1243324Y (es) | Instrumento para fisioterapia |